EurekAlert! Science News Releases·2 min read·hard
NRG Oncology SPPORT analysis highlights potential role of genetic testing in identifying prostate cancer patients who may benefit most from hormone therapy
✦AI Summary
A clinical trial analysis from NRG Oncology suggests that the PAM50 genomic classifier can identify prostate cancer patients who are most likely to benefit from hormone therapy. The study focused on the Luminal B molecular subtype to better tailor treatment plans.
Why it matters
This research supports the move toward precision medicine, potentially sparing patients from unnecessary treatments while improving outcomes for those who need hormone therapy.
BOSTON, MA – A recent analysis of the NRG-RTOG 0534 “SPPORT” clinical trial evaluated the Luminal B (LumB) molecular subtype…
healthscience
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in